Ashvattha Therapeutics announced positive interim Phase 2 results for its subcutaneously administered nanomedicine, migaldendranib (MGB), designed to treat retinal...

A real-world study published in JCO Precision Oncology suggests that Myriad Genetics’ RiskScore tool, integrated into its MyRisk Hereditary...

Syndax Pharmaceuticals announced positive Phase 2 trial results for revumenib, a menin inhibitor, in patients with relapsed or refractory...

Arcutis Biotherapeutics announced positive Phase 3 trial results for ZORYVE foam 0.3% in treating scalp and body psoriasis. The...

E-therapeutics presented preclinical data at the European Association for the Study of the Liver (EASL) Congress on ETX-312, a...

Alkeus Pharmaceuticals released additional Phase 2 clinical trial (SAGA) data for gildeuretinol, an oral treatment for geographic atrophy (GA)...

Inspira Technologies’ INSPIRA™ ART100 system has been approved for clinical validation by Israel’s largest healthcare provider during organ transplant...

Alterity Therapeutics will present data from its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) at...

Assembly Biosciences presented preclinical and in vitro data for two hepatitis drug candidates, ABI-6250 and ABI-4334, at the European...

Alzamend Neuro is partnering with QMENTA to utilize their AI-driven imaging platform in five upcoming Phase II clinical trials...